Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Dinitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | BCHE | P06276 | 6/20 | 0.63 |
| ▸ | GSR | P00390 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Dinitrate SCHEMBL3864281 | 1.00 | ALDH1A1 (0.88) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL19528695 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL9439417 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL29532755 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL309369 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL8253 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL1553054 | 0.94 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3008938 | 0.91 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL714959 | 0.91 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL919022 | 0.91 | MAPT (0.93) | ALDH1A1MAPTBCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-10946197-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2021-03-16 | — | — | US | disclosed |
| US-10702533-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2020-07-07 | — | — | US | disclosed |
| US-10086071-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170128457-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2017-05-11 | — | — | US | disclosed |
| US-9585851-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160367807-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2016-12-22 | — | — | US | disclosed |
| US-20140086872-A1 | Methods of Treating a Subject for a Condition | PALO ALTO INVESTORS (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569277-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120270876-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2012-10-25 | — | — | US | disclosed |
| US-20050256028-A1 | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase | PALO ALTO INVESTORS | 2005-11-17 | — | — | US | disclosed |
| US-20050240241-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-10-27 | — | — | US | disclosed |
| US-20050153885-A1 | administering aldosterone antagonists such as spironolactone and eplerenone, to increasing the parasympathetic and sympathetic activity | PALO ALTO INVESTORS | 2005-07-14 | — | — | US | disclosed |
| US-20050143378-A1 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-06-30 | — | — | US | disclosed |
| US-20050021092-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-01-27 | — | — | US | disclosed |
| EP-0777483-B1 | METHODS AND MEANS FOR DRUG ADMINISTRATION | PHARMACIA AB (SE) | 2003-05-02 | — | — | EP | disclosed |
| US-5952378-A | Methods and means for drug administration | PHARMACIA & UPJOHN AB (SE) | 1999-09-14 | — | — | US | disclosed |
| EP-0777483-A1 | METHODS AND MEANS FOR DRUG ADMINISTRATION | Pharmacia AB (SE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005840-A1 | METHODS AND MEANS FOR DRUG ADMINISTRATION | PHARMACIA AB (SE) | 1996-02-29 | — | — | WO | disclosed |
| US-5472710-A | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture | SCHWARZ PHARMA AG (DE) | 1995-12-05 | — | — | US | disclosed |